<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        30-444-08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EMIMYCIN 500 MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        40.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLOBAL PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLOBAL PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 423]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            MANAYER NAJD TRADING MEDICAL NEEDS CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLOBAL PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Clarithromycin belongs to a group of medicine called macrolide antibiotics. Antibiotics stop the growth of bacteria which cause infections.</p><p>Emimycin is used to treat following infections:</p><p>● Chest infections such as bronchitis and pneumonia,</p><p>● Throat and sinus infections,</p><p>● Skin and soft tissue infections,</p><p>● Helicobacter pylori infections associated with duodenal ulcers.</p><p>Emimycin is indicated in adults and children 12 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Emimycin if you:</strong></p><p>● know that you are <strong>allergic </strong>to clarithromycin or other macrolide antibiotics such as erythromycin or azithromycin, or any of the other ingredients of Emimycin.</p><p>● are taking medicines called ergot alkaloid tablets (e.g. ergotamine or dihydroergotamine) or use ergotamine inhalers for migraine.</p><p>● are taking medicines called terfenadine or astemizole (widely taken for hay fever or allergies) or cisapride (for stomach disorders) or pimozide (for mental health problems) as combining these drugs can sometimes cause serious disturbances in heart rhythm. Consult your doctor for advice on alternative medicines.</p><p>● are taking lovastatin or simvastatin (HMG-CoA reductase inhibitors, commonly known as statins, used to lower levels of cholesterol (a type of fat) in the blood).</p><p>● are taking oral midazolam (a sedative)</p><p>● have abnormally low levels of potassium in the blood (a condition known as hypokalaemia)</p><p>● are taking other medicines which are known to cause serious disturbances in heart rhythm</p><p>● You or someone in your family has a history of heart rhythm disorders (ventricular cardiac arrhythmia, including torsades de pointes) or abnormality of electrocardiogram (ECG, electrical recording of the heart) called &ldquo;long QT syndrome&rdquo;.</p><p>● have <strong>severe </strong>liver disease with kidney disease.</p><p>● You are taking medicines called ticagrelor or ranolazine (for heart attack, chest pain or angina)</p><p>● Are taking colchicine (usually taken for gout)</p><p><strong>Take special care with Emimycin</strong></p><p>● If you have abnormally low levels of magnesium in your blood (hypomagnesaemia) consult your doctor before taking these tablets.</p><p><strong>Emimycin is not suitable for use in children under 12 years of age.</strong></p><p><strong>Warnings and precautions:</strong></p><p>Talk to your doctor or pharmacist before taking Emimycin;</p><p>● If you have heart problems (e.g. heart disease, heart failure, an unusually slow heart rate, or low levels of magnesium in the blood (hypomagnesaemia))</p><p>● you are pregnant or breast-feeding</p><p>● if you have, or are prone to, fungal infections (e.g. thrush)</p><p>● if you have any liver or kidney problems</p><p><strong>Other medicines and Emimycin:</strong></p><p>You should not take Emimycin if you are taking any of the medicines listed in the section above &ldquo;Do not take Emimycin if you;&rdquo;</p><p>Tell your doctor if you are taking, have recently taken or might take any of the following medicines as your dose may need to be changed or you may need to have regular tests performed.</p><p>● Digoxin, disopyramide or quinidine (for heart problems)</p><p>● carbamazepine, valproate, phenobarbital or phenytoin (for epilepsy)</p><p>● atorvastatin, rosuvastatin (HMG-CoA reductase inhibitors, commonly known as statins, and used to lower levels of cholesterol (a type of fat) in the blood). Statins can cause rhabdomyolosis (a condition which cause the breakdown of muscle tissue which can result in kidney damage) and signs of myopathy (muscle pain or muscle weakness) should be monitored.</p><p>● theophylline (used in patients with breathing difficulties such as asthma)</p><p>● triazolam, alprazolam or intravenous or oromucosal midazolam (sedatives)</p><p>● Cilostazol (for poor circulation)</p><p>● Methylprednisolone (a corticosteroid)</p><p>● warfarin (for thinning the blood)</p><p>● Nateglinide, pioglitazone, repaglinide, rosiglitazone or insulin (used to lower blood glucose levels)</p><p>● Gliclazide or glimepiride (sulphonylureas used in the treatment of type II diabetes)</p><p>● Vinblastine (for treatment of cancer)</p><p>● Ciclosporin, sirolimus or tacrolimus (immune suppressants)</p><p>● etravirine, efavirenz, nevirapine, ritonavir, zidovudine, atazanavir, saquinavir (anti-viral drugs used in the treatment of HIV)</p><p>● Rifampicin, rifapentine, fluconazole, itraconazole or rifabutin (used for treatment of certain bacterial infections)</p><p>● Tolterodine (for overactive bladder)</p><p>● Verapamil, amlodipine, diltiazem (for high blood pressure)</p><p>● Sildenafil, vardenafil and tadalafil (for impotence in adult males or for use in pulmonary arterial hypertension (high blood pressure in the blood vessels of the lung))</p><p>● St John&rsquo;s Wort (a herbal product used to treat depression)</p><p>● Quetiapine or other antipsychotic medicines</p><p>● Other macrolide medicines</p><p>● Lincomycin and clindamycin (lincosamides &ndash; a type of antibiotic)</p><p>Please tell your doctor if you are taking oral contraceptive pills and diarrhea or vomiting occurs, as you may need to take extra contraceptive precautions such as using a condom.</p><p>Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription.</p><p><strong>Taking Emimycin with food and drink</strong></p><p>Emimycin may be taken with or without food.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine, as the safety of</p><p>Emimycin in pregnancy and breast-feeding is not known.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>Emimycin may make you feel dizzy or drowsy. If they affect you in this way do not drive, operate machinery or do anything that requires you to be alert.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Do not give these tablets to children under 12 years. Your doctor will prescribe another suitable medicine for your child.</p><p><strong>The dose of Clarithromycin varies with the condition being treated. Always take the tablets exactly as your doctor has told you to. You should check with your doctor or pharmacist if you are not sure.</strong></p><p>Emimycin should be swallowed with at least half a glass of water.</p><p>● <strong>For treating chest infections, throat or sinus infections and skin and soft tissue infections:</strong></p><p>Usual dose of Clarithromycin for adults and children over 12 years is 250mg twice daily for 6 to 14 days, e.g. one 250mg tablet in the morning and one in the early evening.</p><p>Your doctor may increase the dose to 500mg twice daily in severe infections.</p><p>● <strong>For treating Helicobacter pylori infections associated with duodenal ulcers:</strong></p><p>There are a number of effective treatment combinations available to treat Helicobacter pylori in which Emimycin are taken together with one or two other drugs.</p><p>These combinations include the following and are usually taken for 6 to 14 days:</p><p>a) One Clarithromycin 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day plus lansoprazole, 30 mg twice a day.</p><p>b) One Clarithromycin 500 mg tablet taken twice a day together with metronidazole, 400 mg taken twice a day plus lansoprazole, 30 mg twice a day.</p><p>c) One Clarithromycin 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day or metronidazole, 400 mg taken twice a day plus omeprazole, 40 mg a day.</p><p>d) One Clarithromycin 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day plus omeprazole, 20 mg taken once a day.</p><p>The treatment combination that you receive may differ slightly from the above. Your doctor will decide which treatment combination is the most suitable for you. If you are unsure which tablets you should be taking or how long you should be taking them for, please consult your doctor for advice.</p><p><strong>If you take more Emimycin than you should</strong></p><p>If you or accidentally take more Emimycin in one day than your doctor has told you to, or if a child accidentally swallows some tablets, contact your doctor or nearest hospital emergency department immediately. An overdose of Emimycin is likely to cause vomiting and stomach pains.</p><p><strong>If you forget to take Emimycin</strong></p><p>If you forget to take a clarithromycin tablet, take it as soon as you remember. If it is almost time for your next tablet, do not take the missed tablet and just carry on as before. Do not take a double tablet to make up for a forgotten tablet.</p><p><strong>If you stop taking Emimycin:</strong></p><p>Do not stop taking Emimycin, even if you feel better. It is important to take the tablets for as long as the doctor has told you to, otherwise the problem might come back.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p><p><strong>4. Possible side effects</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Emimycin can cause side effects, although not everybody gets them.</p><p>Contact a doctor immediately if you experience a serious skin reaction: a red, scaly rash with bumps under the skin and blisters (exanthematous pustulosis). The frequency of this side effect is not known (cannot be estimated from the available data).</p><p><strong>If you suffer from any of the following at any time during your treatment STOP TAKING your tablets and contact your doctor immediately:</strong></p><p>● severe or prolonged diarrhoea, which may have blood or mucus in it. Diarrhoea may occur over two months after treatment with clarithromycin, in which case you should still contact your doctor.</p><p>● a rash, difficulty breathing, fainting or swelling of the face, tongue, lips, eyes and throat.</p><p>This is a sign that you may have developed an allergic reaction.</p><p>● severe skin reactions such as painful blistering of the skin, mouth, lips, eyes and genitals (symptoms of a rare allergic reaction called Stevens-Johnson syndrome/toxic epidermal necrolysis).</p><p>● yellowing of the skin (jaundice), skin irritation, pale stools, dark urine, tender abdomen or loss of appetite. These are signs that your liver may have inflammation and not be working properly.</p><p>● Muscle pain or weakness known as rhabdomyolysis (a condition which causes the breakdown of muscle tissue which can result in kidney damage).</p><p>● Rare allergic skin reactions which cause severe illness with ulceration of the mouth, lips and skin which causes severe illness with rash, fever and inflammation of internal organs</p><p>(DRESS)</p><p><strong>Other side effects</strong></p><p>Common side effects (may affect up to 1 in 10 people) include;</p><p>● headache</p><p>● difficulty sleeping</p><p>● changes in sense of taste</p><p>● widening of blood vessels</p><p>● stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea</p><p>● increased sweating</p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 people) include;</p><p>● high temperature</p><p>● swelling, redness or itchiness of the skin. Sometimes brown scales may appear</p><p>● oral or vaginal &lsquo;thrush&rsquo; (a fungal infection)</p><p>● inflammation of the stomach and intestines</p><p>● decrease of the levels of blood platelets (blood platelets help stop bleeding)</p><p>● decrease in white blood cells (leukopenia)</p><p>● decrease in neutrophils (neutropenia)</p><p>● stiffness</p><p>● chills</p><p>● increase of eosinophils (white blood cells involved in immunity)</p><p>● exaggerated immune response to a foreign agent</p><p>● lack or loss of appetite</p><p>● anxiety, nervousness</p><p>● drowsiness, tiredness, dizziness or shaking</p><p>● involuntary muscle movements</p><p>● ringing in the ears or hearing loss</p><p>● vertigo</p><p>● chest pain or changes in heart rhythm such as palpitations or an irregular heartbeat</p><p>● asthma: lung disease associated with tightening of air passages, making breathing difficult</p><p>● nose bleed</p><p>● blood clot that causes sudden blockage in a lung artery (pulmonary embolism)</p><p>● inflammation of the lining of the gullet (oesophagus) and lining of the stomach</p><p>● anal pain</p><p>● bloating, constipation, wind, burping</p><p>● dry mouth</p><p>● situation where the bile (fluid make by the liver and stored in the gallbladder) cannot flow from the gallbladder to the duodenum (cholestasis)</p><p>● inflammation of the skin characterized by the presence of the bullae which are filled with fluid, itchy and painful rash</p><p>● muscle spasms, muscle pain or loss of muscle tissue. If your child suffers from myasthenia gravis (a condition in which the muscles become weak and tire easily) clarithromycin may worsen these symptoms.</p><p>● Raised abnormal kidney and liver function blood test and raised blood tests</p><p>● Feeling weak, tired and having no energy</p><p><strong>Not known side effects</strong> (frequency cannot be estimated from the available data)</p><p>● Inflammation of the colon</p><p>● Bacterial infection of the outer layers of skin</p><p>● Reduction in the level of certain blood cells (which can make infections more likely or increase the risk of bruising or bleeding)</p><p>● confusion, loss of bearings, hallucinations (seeing things), change in sense of reality or panicking, depression, abnormal dreams or nightmares and mania (feeling of elation or over-excitement)</p><p>● convulsion (fits)</p><p>● paraesthesia, more commonly known as &lsquo;pins and needles&rsquo;</p><p>● loss of taste or smell or inability to smell properly</p><p>● type of heart rhythm disorder (Torsade de pointes, ventricular tachycardia)</p><p>● loss of blood (haemorrhage)</p><p>● inflammation of the pancreas</p><p>● discolouration of the tongue and/or teeth</p><p>● Acne</p><p>● Change in the levels of products produced by the kidney, inflammation of the kidney or an inability of the kidney to function properly (you may notice tiredness, swelling or puffiness in the face, abdomen, thighs or ankles or problems with urination).</p><p>If you get any side effects, talk to your doctor, or pharmacist .This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep all medicines out of the sight and reach of children. Do not store above 30<sup>◦ </sup>C. Store in a dry place. Protect from light. Do not use Emimycin after the expiry date which is stated after &lsquo;EXP&rsquo; on the blister and carton. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is clarithromycin. Each film-coated tablet contains clarithromycin USP 500mg. The other ingredients are :</p><p><strong><u>Tablet excipients</u></strong>: polysorbate, Colloidal Anhydrous silica, Microcrystalline Cellulose, Maize starch, Povidone, Pregelatinised Starch, Magnesium stearate, Stearic acid, Purified talc, Croscarmellose sodium. <strong><u>Coating excipients</u></strong>: Purified talc, Hypromellose, Polyethylene Glycol, Titanium dioxide, Simethicone emulsion</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Emimycin tablets are White to off white oval film coated tablets, embossed "GP34" on one side and plain on the other side. Emimycin tablets are available in container packs of 14 tablets (7’s blister X 2)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Globalpharma Co. LLC, P. O. Box 72168, Dubai, UAE</p><p>Tel: +97148090900, Email: info@globalpharma.ae</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2019 (RLD10/18)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي كلاريثرومايسين إلى مجموعة من الأدوية تُسمى المضادات الحيوية الماكروليدية. تُوقِف المضادات الحيوية نمو البكتيريا التي تسبِّب العدوى.</p><p dir="RTL">يُستَخدَم إميمايسين أقراص لعلاج العدوى التَّالية:</p><p dir="RTL">&middot;&nbsp;&nbsp; عدوى الصدر مثل التهاب الشُّعَب الهوائية، والالتهاب الرئوي.</p><p dir="RTL">&middot;&nbsp;&nbsp; عدوى الحَلْق والجيوب الأنفية.</p><p dir="RTL">&middot;&nbsp;&nbsp; عدوى الجلد والأنسجة الرخوة.</p><p dir="RTL">&middot;&nbsp;&nbsp; عدوى <em>بكتيريا المَلْوِيَّة البَوَّابية</em> المصاحبة لقرح الإثنا عشر.</p><p dir="RTL">يُستَخدَم إميمايسين في البالغين والأطفال بعُمْر ١٢ عامًا فأكثر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول إميمايسين في الحالات التَّالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كان لديك <strong>حساسية</strong> تجاه كلاريثرومايسين أو المُضادَّات الحَيَوِيَّة الماكْروليدِيّة مثل: إريثروميسين، أو أزيثروميسين، أو أي من المكونات الأخرى في إميمايسين.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول أدوية تُسمى أقراص قلويدات الإرجوت (على سبيل المثال: إرجوتامين أو ثُنائِيّ هيدرات الإرجوتامين) أو تستخدم أجهز استنشاق إرجوتامين لعلاج الصُّداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول أدوية تُسمى تيرفينادين، أو أستيمايزول (يتم تناوُله على نطاق واسع لعلاج حُمَّى القش أو الحساسية)، أو سيسابريد (لعلاج اضطرابات المعدة)، أو بيموزيد (لعلاج مشاكل الصحة النفسية)؛ إذ إنَّ تناوُل هذه العقاقير بالتَّزامن يُمكِن أن يُسَبب اضطرابات خطيرة في النظم القلبي. استشر طبيبك حول الأدوية البديلة.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول لوفاستاتين أو سيمفاستاتين (مثبطات إنزيم مختزلة التَّميم الإنزيمي هيدروكسي ميثيل الجلوتيريل، المعروفة عادة باسم الستاتينات، والتي تُستَخدَم لخفض مستويات الكوليسترول [نوع من الدهون] في الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول ميدازولام عن طريق الفم (دواء مهدئ).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانت مستويات البوتاسيوم بالدَّم لديك منخفضة بصورة غير طبيعية (حالة تُسمى نقص بوتاسيوم الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى معروف بأنها تسبب اضطرابات خطيرة في النظم القلبي.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كان لديك أو كان لدى أحد أفراد عائلتك تاريخ مرضي من الإصابة باضطرابات النَّظم القلبي (اضطرابات النَّظم القلبي البطيني، بما في ذلك التفاف النقاط (إحدى العلامات برسم القلب) أو نتائج غير طبيعية لرسم القلب الكهربائي (مخطط كهربية القلب، تسجيل كهربية القلب) تُسمى &quot;متلازمة إطالة فترة QT&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كان لديك أمراض كبدية شديدة مصاحبة لأمراض بالكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول أدوية تُسمى تيكاجريلور أو رانولازين (لعلاج النوبة القلبية، ألم الصَّدر، أو الذبحة الصَّدرية).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول كُولْشيسين (يتم تناوُله عادةً لعلاج مرض النَّقْرس).</p><p dir="RTL"><strong>توخ حذرًا خاصًّا مع إميمايسين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; استشر طبيبك قبل تناول هذه الأقراص إذا كانت مستويات الماغنيسيوم بالدَّم لديك منخفضة بصورة غير طبيعية (نقص الماغنسيوم بالدَّم).</p><p dir="RTL"><strong>إميمايسين غير مناسب للاستخدام في الأطفال دون سن ١٢ سنة.</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات: </strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناوُل إميمايسين</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كان لديك مشاكل بالقلب (على سبيل المثال: مرض بالقلب، أو فشل القلب، أو بطء معدل ضربات القلب بشكل غير عادي، أو انخفاض مستويات الماغنيسيوم بالدَّم (نقص الماغنسيوم بالدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنتِ حاملًا أو مُرضعًا.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانت لديك إصابة، أو من المعرضين للإصابة بعدوى فطرية (على سبيل المثال: السُّلَاق).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانت لديك أية مشاكل بالكبد أو الكُلى.</p><p dir="RTL"><strong>تناوُل إميمايسين مع أدوية أخرى</strong><strong>:</strong></p><p dir="RTL">يجب ألا تتناول أقراص إميمايسين إذا كنت تتناول أيًّا من الأدوية المُدرَجة في القسم أعلاه &quot;لا تتناول إميمايسين في الحالات التَّالية:&quot;</p><p dir="RTL">يُرجى إبلاغ طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيًّا من الأدوية التَّالية؛</p><p dir="RTL">إذ قد يستلزم الأمر تغيير الجرعة أو قد تحتاج إلى الخضوع إلى اختبارات بصفة منتظمة.</p><p dir="RTL">&middot;&nbsp;&nbsp; ديجوكسِين، أو ديسوبيراميد، أو كينيدين (يُستَخدَم لعلاج مشاكل القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp; كَرْبامازِيبين، أو فالبروات، أو فينوباربيتال، أو فينيتوين (لعلاج الصَّرع).</p><p dir="RTL">&middot;&nbsp;&nbsp; أتورفاستاتين، روزيوفاستاتين (مثبطات إنزيم مختزلة التَّميم الإنزيمي هيدروكسي ميثيل الجلوتيريل)، المعروفة باسم الستاتينات، والتي تُستَخدَم لخفض مستويات الكوليسترول [نوع من الدهون] في الدَّم). قد تُسَبب الستاتينات انحلال الربيدات (حالة تُسَبب انحلال النسيج العضلي مما قد يُؤدي إلى تلف الكُلى)؛ لذا، يجب مراقبة علامات الإصابة بالاعتلال العضلي (الألم العضلي أو ضعف العضلات).</p><p dir="RTL">&middot;&nbsp;&nbsp; ثيوفيلين (يُستَخدَم في المرضى الذين لديهم صعوبات في التَّنفس مثل الربو).</p><p dir="RTL">&middot;&nbsp;&nbsp; تريازولام، أو ألبرازولام، أو ميدازولام عن طريق الوريد أو عن طريق الأغشية المخاطية للفم (مهدئات).</p><p dir="RTL">&middot;&nbsp;&nbsp; سيلوستازول (لعلاج ضعف الدَّورة الدَّموية).</p><p dir="RTL">&middot;&nbsp;&nbsp; ميثيل بريدنيزولون (كورتيكوستيرويد).</p><p dir="RTL">&middot;&nbsp;&nbsp; وارفارين (لعلاج ترقق الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp; ناتيجلينيد، أو بيوجليتازون، أو ريباجلينيد، أو روزيجليتازون، أو الأنسولين (يُستخدَم لخفض مستويات الجلوكوز بالدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp; جلايكلازيد أو جليميبريد (السلفونيل يوريا التي تُستَخدَم في علاج مرض السُّكَّرِي من النوع 2).</p><p dir="RTL">&middot;&nbsp;&nbsp; فينبلاستين (لعلاج السرطان).</p><p dir="RTL">&middot;&nbsp;&nbsp; سيكلوسبورين، أو سيروليموس، أو تاكروليموس (كابتات المناعة).</p><p dir="RTL">&middot;&nbsp;&nbsp; إترافيرين، إيفافيرينز، نيفيرابين، ريتونافير، زيدوفودين، أتازانافير، ساكوينافير (عقاقير مضادة للفيروسات تُستَخدَم في علاج فيروس نقص المناعة البشري).</p><p dir="RTL">&middot;&nbsp;&nbsp; ريفامبيسين، أو ريفابينتين، أو فلوكونازول، أو أتراكونازول، أو ريفابوتين (يُستَخدَم لعلاج بعض العدوى البكتيرية).</p><p dir="RTL">&middot;&nbsp;&nbsp; تولتيرودين (لعلاج فرط نشاط المثانة).</p><p dir="RTL">&middot;&nbsp;&nbsp; فيراباميل، أملوديبين، ديلتِيازِيم (لعلاج ارتفاع ضغط الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp; سيلدينافيل، فاردينافيل، تادالافيل (يُستَخدَم لعلاج العُنَّة [اضطرابات الانتصاب] في الذكور البالغين أو للاستخدام في ارتفاع ضغط الدَّم الشرياني الرئوي (ارتفاع ضغط الدَّم في الأوعية الدَّموية في الرئة)).</p><p dir="RTL">&middot;&nbsp;&nbsp; نبتة سانت جونز (منتج عشبي يُستخدم لعلاج الاكتئاب).</p><p dir="RTL">&middot;&nbsp;&nbsp; كيوتيابين أو أدوية مضادات الذهان الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp; الأدوية الماكْروليدِيّة الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp; لينكوميسين وكلينداميسين (اللينكوساميدات - نوع من المضادات الحيوية).</p><p dir="RTL">يُرجى إخبار طبيبك عما إذا كنت تتناولين حبوبًا عن طريق الفم لمنع الحمل وما إذا تعرضت لإسهال أو قيء؛ فقد تحتاجين إلى اتخاذ احتياطات إضافية لمنع الحمل مثل استخدام الواقي الأنثوي.</p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أيَّة أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL"><strong>تناوُل إميمايسين مع الطعام والشراب</strong></p><p dir="RTL">يُمكن تناوُل إميمايسين مع الطعام أو بدونه.</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كُنتِ حاملًا أو مُرضعًا، أو تعتقدين أنكِ حامل أو تُخطِّطين لذلك، فاستشيري طبيبك أو الصيدلي الخاص بك قبل تناوُل هذا الدَّواء؛ إذ إنه من غير المعروف الأمان الخاص بأقراص إميمايسين أثناء الحمل والرضاعة الطبيعية.</p><p dir="RTL">استشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تجعلك أقراص إميمايسين تشعر بالدوخة أو النُّعاس. إذا أثَّر عليك بهذه الطريقة فلا تقم بالقيادة، أو تشغيل الآلات، أو فعل أيّ شيء يتطلَّب أن تكون يقظًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">لا تعط الأقراص إلى أطفال أقل من ١٢ عامًا. سيصف لك طبيبك دواء آخر مناسبًا لطفلك.</p><p dir="RTL"><strong>تختلف جرعة كلاريثرومايسين باختلاف الحالة التي يتم علاجها</strong><strong>. </strong><strong>تناول الأقراص دائمًا كما أخبرك طبيبك بالضبط</strong><strong>.</strong> <strong>يجب مُراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التناوُل</strong><strong>.</strong></p><p dir="RTL">يجب ابتلاع إميمايسين مع نصف كوب على الأقل من الماء.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp; </strong><strong>لعلاج عدوى الصدر أو الحَلْق أو عدوى الجيوب الأنفية والجلد والأنسجة الرَّخوة</strong><strong>:</strong></p><p dir="RTL">تبلغ الجرعة المعتادة من كلاريثرومايسين للبالغين والأطفال الذين تتجاوز أعمارهم ١٢ عامًا؛ قرصًا واحدًا ٢٥٠ ملجم</p><p dir="RTL">مرة واحدة يوميًّا لمدة تتراوح بين ٦ و ١٤ يومًا، على سبيل المثال، قرص واحد ٢٥٠ ملجم في الصباح وآخر في بداية</p><p dir="RTL">المساء.</p><p dir="RTL">قد يُزيد طبيبك الجرعة إلى ٥٠٠ ملجم مرتين يوميًّا في حالات العدوى الشديدة.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp; </strong><strong>لعلاج عدوى بكتيريا المَلْوِيَّة البَوَّابيةالمصاحبة لقرح الإثنا عشر</strong><strong>:</strong></p><p dir="RTL">هناك عدد من التركيبات العلاجية الفعَّالة المُتاحة لعلاج بكتيريا المَلْوِيَّة البَوَّابية والتي يتم فيها تناوُل إميمايسين بمصاحبة</p><p dir="RTL">واحد أو أكثر من العقاقير الأخرى.</p><p dir="RTL">تشمل هذه التركيبات ما يلي ويتم تناوُلها عادةً لمدة ٦ إلى ١٤ يومًا:</p><p dir="RTL">أ) قرصًا واحدًا من كلاريثرومايسين ٥٠٠ ملجم مرتين في اليوم بمصاحبة أموكسيسيلين ١٠٠٠ &nbsp;ملجم مرتين في اليوم بالإضافة إلى لانسوبرازول ٣٠ ملجم مرتين في اليوم.</p><p dir="RTL">ب) قرصًا واحدًا من كلاريثرومايسين ٥٠٠ ملجم مرتين في اليوم بمصاحبة ميترونيدازول ٤٠٠ ملجم مرتين في اليوم بالإضافة إلى لانسوبرازول ٣٠ ملجم مرتين في اليوم.</p><p>ج) قرصًا واحدًا من كلاريثرومايسين ٥٠٠ ملجم مرتين في اليوم بمصاحبة أموكسيسيلين ١٠٠٠ &nbsp;ملجم مرتين في اليوم أو ميترونيدازول ٤٠٠ ملجم مرتين في اليوم بالإضافة إلى أوميبرازول ٤٠ ملجم في اليوم</p><p dir="RTL">د) قرصًا واحدًا من كلاريثرومايسين ٥٠٠ ملجم مرتين في اليوم بمصاحبة أموكسيسيلين ١٠٠٠ ملجم مرتين في اليوم بالإضافة إلى أوميبرازول ٢٠ ملجم في اليوم.</p><p dir="RTL">قد يختلف العلاج المُركَّب الذي تتلقاه اختلافًا طفيفًا عن المذكور أعلاه. سيُقرر طبيبك ما هي تركيبة العلاج الأنسب بالنسبة لك. إذا لم تكن متأكدًا بشأن الأقراص التي يجب عليك تناوُلها أو المدة التي يحب عليك تناوُل الأقراص فيها، فيُرجى استشارة طبيبك.</p><p dir="RTL"><strong>إذا تناولت كمية من إميمايسين أكثر مما يجب</strong></p><p dir="RTL">إذا تناولت كمية من إميمايسين أكثر مما أخبرك الطبيب بتناوله في يوم واحد عن طريق الخطأ، أو إذا ابتلع الطِّفل بعض الأقراص عن طريق الخطأ، فاتصل بطبيبك أو قسم الطَّوارئ بأقرب مستشفى فورًا. قد يُؤدي تناوُل جرعة زائدة من إميمايسين إلى القيء، وألم بالمعدة.</p><p dir="RTL"><strong>إذا أغفلت تناوُل إميمايسين</strong></p><p dir="RTL">إذا أغفلت تناوُل قرص كلاريثرومايسين، فتناوُله بمُجرد تذكُّرك له. إذا كان قد حان موعد الجُرعة التَّالية تقريبًا، فتجاوَز الجُرعة التي أغفلتها واستمر في تناوُل الجرعات كما كنت. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL"><strong>إذا توقفت عن تناول إميمايسين</strong><strong>:</strong></p><p dir="RTL">لا تتوقف عن تناوُل إميمايسين أقراص، حتى إذا كنت تشعر بتحسن. من المهم للغاية أن تتناول الأقراص طوال المدة التي وصفها لك طبيبك، وإلا قد تتكرر المشكلة مرة أخرى.</p><p dir="RTL"><strong>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب إميمايسين آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">اتصل بأحد الأطباء فورًا إذا أُصِبت بتفاعل جلدي خطير: طفح جلدي محمر ومتقشر مع نتوءات تحت الجلد وبثور (طفح جلدي ظاهري صديدي). معدل تكرار الآثار الجانبية غير معروف (لا يمكن تقديره من واقع البيانات المتاحة).</p><p dir="RTL"><strong>إذا كُنت تعاني من أي مما يلي في أي وقت أثناء العلاج توقف عن تناول أقراصك واتصل بطبيبك فورًا</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; إسهال شديد أو مستمر لفترات طويلة، قد يكون به دم أو مخاط. قد يحدث إسهال على مدى شهرين بعد العلاج بكلاريثرومايسين، في هذه الحالة يجب عليك الاتصال بطبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp; طفح جلدي، صعوبة التَّنفس، إغماء أو تورُّم الوجه، اللسان، الشفتين، العينين والحَلْق.</p><p dir="RTL">&middot;&nbsp;&nbsp; تعَد هذه علامة على أنك قد تكون أُصِبت بتفاعلات حساسية.</p><p dir="RTL">&middot;&nbsp;&nbsp; تفاعلات شديدة بالجلد مثل: ظهور نفطات بالجلد والفم والشفتين والعينين والأعضاء التَّناسلية (أعراض الإصابة بتفاعل حساسية نادر يُسمى متلازمة ستيفنز جونسون/ انحلال البشرة النخري التَّسَمُّمِيّ).</p><p dir="RTL">&middot;&nbsp;&nbsp; اصفرار الجلد (يرقان)، تهيُّج الجلد، براز فاتح اللون، بول داكن، ألم بالبطن أو فقدان الشهية. قد تكون هذه علامات على التهاب كبدك وأنه لا يعمل بشكل سليم.</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم عضلي أو ضعف يعرف بانحلال الربيدات (حالة تُسَبب تحلل النَّسيج العضلي مما قد يُؤدي إلى تلف الكُلى).</p><p dir="RTL">&middot;&nbsp;&nbsp; تفاعلات حساسية نادرة بالجلد تسبب مرضًا شديدًا مع تقرح الفم، والشفتين، والجلد مما يُسبب مرضًا شديدًا مع الإصابة بطفح جلدي، وحمى، والتهاب الأعضاء الداخلية (الطفح الجلدي الدَّوائي المصحوب بكثرة خلايا اليُوزينِيَّات والأعراض الجهازية).</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL">الآثار الجانبية الشَّائعة (قد تُؤثر في ما يصل إلى ١ من كل ١٠&nbsp;أشخاص) تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp; صداعًا. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●&nbsp; صعوبة في النوم.</p><p dir="RTL">&middot;&nbsp;&nbsp; تغيُّرًا بحاسة التَّذوق.&nbsp;&nbsp;&nbsp; ● اتساع الأوعية الدَّموية.</p><p dir="RTL">&middot;&nbsp;&nbsp; مشاكل بالمعدة مثل: شعور بالإعياء، قيء، ألم بالمعدة، عسر الهضم، إسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp; تعرُّقًا شديدًا.</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> (قد تُؤثر على ما يصل إلى ١ من كل ١٠٠ شخص) تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp; ارتفاع درجة الحرارة.&nbsp;&nbsp;&nbsp; ●&nbsp; تورُّمًا، احمرارًا أو حكة بالجلد. قد تظهر حَراشِف بنية</p><p dir="RTL">&middot;&nbsp;&nbsp; &quot;سُلَاقًا&quot; فمويًّا أو مهبليًّا (عدوى فطرية).&nbsp;&nbsp;&nbsp;&nbsp; ●&nbsp; التهاب المعدة والأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاض مستويات الصَّفائح الدَّموية (تُساعد الصَّفائح الدَّموية في إيقاف النزيف).</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاضًا في خلايا الدَّم البيضاء (نقص كريات الدَّم البيضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاضًا في خلايا العدلات (قلة خلايا العَدِلات).</p><p dir="RTL">&middot;&nbsp;&nbsp; تصلُّب العضلات.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ● قشعريرة.</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة الحمضات (خلايا الدَّم البيضاء المشاركة في المناعة).</p><p dir="RTL">&middot;&nbsp;&nbsp; استجابة مناعية مبالغًا فيها للعوامل الغريبة.</p><p dir="RTL">&middot;&nbsp;&nbsp; نقص أو فقدان الشهية.&nbsp; ● قلقًا، عصبية.</p><p dir="RTL">&middot;&nbsp;&nbsp; نُعاسًا، تعبًا، دوخة أو ارتجافًا.</p><p dir="RTL">&middot;&nbsp;&nbsp; حركات عضلية غير إرادية.</p><p dir="RTL">&middot;&nbsp;&nbsp; الطنين بالأذنين أو فقدان السَّمع.</p><p dir="RTL">&middot;&nbsp;&nbsp; دوارًا.</p><p dir="RTL">&middot;&nbsp;&nbsp; ألمًا بالصَّدر أو تغيُّرات في النَّظم القلبي مثل: الخَفَقان أو عدم انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp; الربو: مرضًا بالرئة مصحوبًا بضيق الممرات الهوائية، مما يجعل التَّنفس صعبًا.</p><p dir="RTL">&middot;&nbsp;&nbsp; نزيف الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp; الجلطة الدَّموية التي تُسبب انسدادًا مفاجئًا في الشريان الرئوي (انصمامًا رئويًّا).</p><p dir="RTL">&middot;&nbsp;&nbsp; التهاب بطانة المريء وبطانة المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم الشَّرج.</p><p dir="RTL">&middot;&nbsp;&nbsp; الانتفاخ، والإمساك، والريح والتجشؤ.</p><p dir="RTL">&middot;&nbsp;&nbsp; جُفاف الفَم.</p><p dir="RTL">&middot;&nbsp;&nbsp; حالة تكون فيها العصارة الصفراوية (سائل يُفرز بواسطة الكبد ويُخزن في المرارة) غير قادرة على التَّدفق من المرارة إلى الإثنا عشر (ركود صفراوي).</p><p dir="RTL">&middot;&nbsp;&nbsp; التهاب الجلد الذي يتسم بوجود الفقاعات الممتلئة بالسائل، وحكة وطفح جلدي مؤلم.</p><p dir="RTL">&middot;&nbsp;&nbsp; تقلصات العضلات، الألم العضلي أو فقدان النَّسيج العضلي. إذا كنت تُعاني من الوهن العضلي الوبيل (حالة تصبح فيها العضلات ضعيفة وتتعب بسهولة) فقد يتسبب كلاريثرومايسين في تفاقم هذه الأعراض.</p><p dir="RTL">&middot;&nbsp;&nbsp; ارتفاع اختبارات الدَّم لوظائف الكُلى والكبد بشكل غير طبيعي وارتفاع اختبارات الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp; الشُّعور بالضَّعف، والتَّعب وعدم وجود طاقة.</p><p dir="RTL"><strong>آثار جانبية غير معروفة </strong>(لا يُمكن تقدير مُعدَّل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp; التهاب القولون.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ● عدوى بكتيرية في طبقات الجلد الخارجية.</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاض في مستوى بعض خلايا الدَّم (مما قد يجعلك أكثر عُرضة للإصابة بعدوى أو زيادة خطر حدوث تكدم أو النزيف).</p><p dir="RTL">&middot;&nbsp;&nbsp; ارتباك، فقدان الاتجاهات، هلاوس (رؤية أشياء غير موجودة)، تغيُّر في الإحساس بالواقع أو هلع، اكتئاب، أحلام غير طبيعية أو كوابيس والهوس (الشعور بانتشاء أو إِثارَة مفرطة).</p><p dir="RTL">&middot;&nbsp;&nbsp; اختلاجات (نوبات).</p><p dir="RTL">&middot;&nbsp;&nbsp; اضطرابات الإحساس، المعروفة عمومًا باسم &quot;وخز [الإبر أو المسامير]&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان حاسة التَّذوق أو الشم أو عدم القدرة على الشَّم بشكل سليم.</p><p dir="RTL">&middot;&nbsp;&nbsp; نوع من اضطراب النظم القلبي (التفاف النقاط، تسرُّع ضربات القَلْب البطيني).</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان الدَّم (نزيف).&nbsp;&nbsp; ● التهاب البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp; تغيُّر لون اللسان و/أو الأسنان.&nbsp; ●&nbsp; حب الشباب</p><p dir="RTL">&middot;&nbsp;&nbsp; تغيُّر في مستويات نواتج الكلى، التهاب الكُلى أو عدم قدرتها على أداء وظائفها بشكل سليم (قد تُلاحظ الشعور بالتَّعب، الإصابة بتورُّم أو انتفاخ في الوجه أو البطن أو الفخذين أو الكاحلين أو مشاكل في التبوُّل).</p><p dir="RTL">إذا لاحظت أي من هذه الآثار الجانبية ، إستشر طبيبك أو الصيدلي الخاص بك&nbsp; . وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحفظ الأدوية بعيدا عن متناول الأطفال ونظرهم. يحفظ في درجة حرارة لا تزيد عن ٣٠ درجة مئوية في مكان جاف بعيدا عن الضوء. لا يستعمل إميمايسين بعد انقضاء تاريخ الصلاحية المدون على الشريط وعلى العبوة بعد كلمة EXP.</p><p dir="RTL">لا ينبغي التخلص من الأدوية في المياه العادمة أو النفايات المنزلية . إسأل الصيدلي الخاص بك عن الطريقة المناسبة للتخلص من الأدوية التي لم تعد بحاجة إليها . فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي كلاريثرومايسين .</p><p dir="RTL">يحتوي كل قرص مغلف على ٥٠٠ ملجم كلاريثرومايسين (طبقا لدستور الأدوية الأمريكي).</p><p dir="RTL">المكونات الأخرى غير الفعالة هي:</p><p dir="RTL"><u>سواغات القرص</u>: بوليسوربات ، سيليكا لامائية غروية ، سيليلوز دقيق التبلور، نشا الذرة ، بوفيدون، نشا معدل، ستيرات المغنيسيوم، حامض الستيريك ، تلك منقى، كروسكارميلوس الصوديوم.</p><p dir="RTL"><u>&nbsp;سواغات غلاف القرص</u> : تلك منقى، هيبروميلّوز ، جليكول بولي إيثيلين، ثنائي أكسيد التيتانيوم، مستحلب سيميثيكون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص إميمايسين أقراص بيضاوية الشكل ذات لون أَبْيَضُ الى أبيض يميل إِلَى الصُّفْرَةِ ، محفور على أحد جانبيها <strong>GP34</strong> والجانب الآخر خال من الحفر. أقراص إميمايسين متوفره في عبوات تحتوي على ۱٤ قرص ( شريطان بكل منهما ٧ أقراص ) .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة جلوبال فارما ذ.م.م. ،&nbsp; ص.ب. ۷۲۱٦٨ ، دبي ، الامارات العربية المتحدة .</p><p dir="RTL">هاتف: /٩٧١٤٨٠٩٠٩٠٠+/&nbsp; ، بريد إلكتروني: info@globalpharma.ae</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر تحديث لهذه النشرة في مايو ۲۰۱٩( RLD10/18)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emimycin 500 mg Film-Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains clarithromycin USP 500mg.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets 
White of off-white oval film coated tablets, embossed with GP 34 on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clarithromycin film-coated tablets are indicated for the treatment of the following bacterial infections, when caused by clarithromycin-susceptible bacteria (see section 4.4 and 5.1).</p><p>&bull; Bacterial pharyngitis</p><p>&bull; Mild to moderate community acquired pneumonia</p><p>&bull; Acute bacterial sinusitis (adequately diagnosed)</p><p>&bull; Acute exacerbation of chronic bronchitis</p><p>&bull; Skin infections and soft tissue infections of mild to moderate severity,</p><p>&bull; In appropriate combination with antibacterial therapeutic regimens and an appropriate ulcer healing agent for the eradication of Helicobacter pylori in patients with Helicobacter pylori associated ulcers (see section 4.2).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The dosage of Clarithromycin film-coated tablets depends on the type and severity of the infection and has to be defined in any case by the physician.</p><p><em>Clarithromycin 500 mg film-coated tablet is not suitable for doses below 500 mg. There are other options for this strength available on the market.</em></p><p><u>Adults and adolescents (12 years and older)</u></p><p>&bull; Standard dosage: The usual dose is 250 mg twice daily (in the morning and in the evening)</p><p>&bull; High dosage treatment (severe infections): The usual dose may be increased to 500 mg twice daily in severe infections.</p><p><u>Children younger than 12 years:</u></p><p>Use of Clarithromycin film-coated tablets is not recommended for children younger than 12 years with a body weight less than 30 kg. Clinical trials have been conducted using clarithromycin pediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension.</p><p>For children with a body weight of more than 30kg, the dose for adults apply.</p><p><u>Dosage in renal functional impairment:</u></p><p>In patients with renal impairment with creatinine clearance less than 30 mL/min, the dosage of clarithromycin should be reduced by one-half, i.e. 250 mg once daily, or 250 mg twice daily in more severe infections. Treatment should not be continued beyond 14 days in these patients.</p><p><u>Patients with hepatic impairment:</u></p><p>Caution should be exercised when administrating clarithromycin in patients with hepatic impairment (see section 4.3 and 4.4).</p><p><u>H. pylori eradication in peptic ulcer disease</u></p><p>For the eradication of&nbsp;<em>H. pylori</em>&nbsp;the selection of antibiotics should consider the individual patient&#39;s drug tolerance, and should be undertaken in accordance with national, regional and local resistance patterns and treatment guidelines.</p><p>Usually clarithromycin is administered in combination with another antibiotic and a proton-pump inhibitor for one week.</p><p>The therapy may be repeated if the patient is still H. pylori-positive</p><p><u>Duration of therapy:</u></p><p>The duration of therapy with Clarithromycin film-coated tablets depends on the type and severity of the infection and has to be defined in any case by the physician.</p><p>&bull; The usual duration of treatment is 7 to 14 days.</p><p>&bull; Therapy should be continued at least for 2 days after symptoms have subsided.</p><p>&bull; In Streptococcus pyogenes (group A beta-haemolytic streptococcus) infections the duration of therapy should be at least 10 days.</p><p>&bull; Combination therapy for the eradication of H. pylori infection should be continued for 7 days.</p><p><u>Method of administration:</u></p><p>The tablet should be swallowed whole with a sufficient amount of fluid (eg. one glass of water).</p><p>Clarithromycin film-coated tablets may be given irrespective of food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clarithromycin is contraindicated in patients with known hypersensitivity to the active substance clarithromycin, to other macrolides or to any of the excipients listed in section 6.1.
Concomitant administration of clarithromycin and any of the following active substances is contraindicated: astemizole, cisapride, pimozide and terfenadine as this may result in QT prolongation (congenital or documented acquired QT prolongation) and cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation and Torsade de Pointes (see section 4.5).
Concomitant administration with ticagrelor or renolazine is contraindicated.
Concomitant administration of clarithromycin and ergotamine or dihydroergotamine is contraindicated, as this may result in ergot toxicity.
Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointe (see sections 4.4 and 4.5).
Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolosed by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see section 4.5).
Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of QT-time).
Clarithromycin should not be used in patients who suffer from severe hepatic failure in combination with renal impairment.
As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in patients taking colchicine.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The physician should not prescribe clarithromycin to pregnant women without carefully weighing the benefits against risk, particularly during the first three months of pregnancy (see section 4.6).</p><p>Caution is advised in patients with severe renal insufficiency (see section 4.2).</p><p>Clarithromycin is principally excreted by the liver. Therefore, caution should be exercised in administering the antibiotic to patients with impaired hepatic function. Caution should also be exercised when administering clarithromycin to patients with moderate to severe renal impairment.</p><p>Cases of fatal hepatic failure (see section 4.8) have been reported. Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products. Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop, such as anorexia, jaundice, dark urine, pruritus, or tender abdomen.</p><p>Pseudomembranous colitis has been reported with nearly all antibacterial agents, including macrolides, and may range in severity from mild to life-threatening. Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents including clarithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of C.difficile. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. Therefore, discontinuation of clarithromycin therapy should be considered regardless of the indication. Microbial testing should be performed and adequate treatment initiated. Drugs inhibiting peristalsis should be avoided.</p><p>There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency. Deaths have been reported in some such patients (see section 4.5). Concomitant administration of clarithromycin and colchicines is contraindicated (see section 4.3).</p><p>Caution is advised regarding concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam, and midazolam (see section 4.5).</p><p>Caution is advised regarding concomitant administration of clarithromycin with other ototoxic drugs, especially with aminoglycosides. Monitoring of vestibular and auditory function should be carried out during and after treatment.</p><p>Cardiovascular Events</p><p>Prolonged cardiac repolarisation and QT interval, imparting a risk of developing cardiac arrhythmia and torsade de pointes, have been seen in treatment with macrolides including clarithromycin (see section 4.8). Therefore as the following situations may lead to an increased risk for ventricular arrhythmias (including torsade de pointes), clarithromycin should be used with caution in the following patients;</p><p>&bull; Patients with coronary artery disease, severe cardiac insufficiency, conduction disturbances or clinically relevant bradycardia</p><p>&bull; Patients with electrolyte disturbances such as hypomagnesaemia. Clarithromycin must not be given to patients with hypokalaemia (see section 4.3).</p><p>&bull; Patients concomitantly taking other medicinal products associated with QT prolongation (see section 4.5).</p><p>&bull; Concomitant administration of clarithromycin with astemizole, cisapride, pimozide and terfendine is contraindicated (see section 4.3).</p><p>&bull; Clarithromycin must not be used in patients with congenital or documented acquired QT prolongation or history of ventricular arrhythmia (see section 4.3).</p><p>Epidemiological studies investigating the risk of adverse cardiovascular outcomes with macrolides have shown variable results. Some observational studies have identified a rare short-term risk of arrhythmia, myocardial infarction and cardiovascular mortality associated with macrolides including clarithromycin. Consideration of these findings should be balanced with treatment benefits when prescribing clarithromycin.</p><p><u>Pneumonia:</u>&nbsp;In view of the emerging resistance of Streptococcus pneumoniae to macrolides, it is important that sensitivity testing be performed when prescribing clarithromycin for community-acquired pneumonia. In hospital-acquired pneumonia, clarithromycin should be used in combination with additional appropriate antibiotics.</p><p><u>Skin and soft tissue infections of mild to moderate severity</u>: These infections are most often caused by Staphylococcus aureus and Streptococcus pyogenes, both of which may be resistant to macrolides. Therefore, it is important that sensitivity testing be performed. In cases where beta&ndash;lactam antibiotics cannot be used (e.g. allergy), other antibiotics, such as clindamycin, may be the drug of first choice. Currently, macrolides are only considered to play a role in some skin and soft tissue infections, such as those caused by Corynebacterium minutissimum, acne vulgaris, and erysipelas and in situations where penicillin treatment cannot be used.</p><p>In the event of severe acute hypersensitivity reactions, such as anaphylaxis, severe cutaneous adverse reactions (SCAR) (e.g. Acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome, and toxic epidermal necrolysis, clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.</p><p>Clarithromycin should be used with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme (see section 4.5).</p><p><u>HMG-CoARreductase Inhibitors (statins):</u>&nbsp;Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see section 4.3). Caution should be exercised when prescribing clarithromycinwith other statins. Rhabdomyolysis has been reported in patients taking clarithromycin and statins. Patients should be monitored for signs and symptoms of myopathy. In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of statin. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered.</p><p><u>Oral hypoglycemic agents/Insulin:</u>&nbsp;The concomitant use of clarithromycin and oral hypoglycemic agents (such as sulfonylurias) and/or insulin can result in significant hypoglycemia. Careful monitoring of glucose is recommended.</p><p><u>Oral anticoagulants:</u>&nbsp;There is a risk of serious hemorrhage and significant elevations in International Normalized Ratio (INR) and prothrombin time when clarithromycin is co-administered with warfarin (see section 4.5). INR and prothrombin times should be frequently monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.</p><p>Use of any antimicrobial therapy, such as clarithromycin, to treat H. pylori infection may select for drug-resistant organisms.</p><p>Long-term use may, as with other antibiotics, result in colonization with increased numbers of non-susceptible bacteria and fungi. If super-infection occur,appropriate therapy should be instituted.</p><p>Attention should also be paid to the possibility of cross resistance between clarithromycin and other macrolide drugs, as well as lincomycin and clindamycin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>The use of the following drugs is strictly contraindicated due to the potential for severe drug interaction effects:</strong></p><p><u>Cisapride, pimozide, astemizole and terfenadine</u></p><p>Elevated cisapride levels have been reported in patients receiving clarithromycin and cisapride concomitantly. This may result in QT prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation and torsades de pointes. Similar effects have been observed in patients taking clarithromycin and pimozide concomitantly (see section 4.3).</p><p>Macrolides have been reported to alter the metabolism of terfenadine resulting in increased levels of terfenadine which has occasionally been associated with cardiac arrhythmias such as QT prolongation, ventricular tachycardia, ventricular fibrillation and torsades de pointes (see section 4.3). In one study in 14 healthy volunteers, the concomitant administration of clarithromycin and terfenadine resulted in a two to three fold increase in the serum level of the acid metabolite of terfenadine and in prolongation of the QT interval which did not lead to any clinically detectable effect. Similar effects have been observed with concomitant administration of astemizole and other macrolides.</p><p><u>Ergotamine/dihydroergotamine</u></p><p>Postmarketing reports indicate that co-administration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm, and ischemia of the extremities and other tissues including the central nervous system. Concomitant administration of clarithromycin and these medicinal products is contraindicated (see section 4.3).</p><p><u>HMG-CoA Reductase Inhibitors (statins)</u></p><p>Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see 4.3) as these statins are extensively metabolized by CYP3A4 and concomitant treatment with clarithromycin increases their plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Reports of rhabdomyolysis have been received for patients taking clarithromycin concomitantly with these statins. If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.</p><p>Caution should be exercised when prescribing clarithromycin with statins. In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of the statin.Use of a statin that is not dependent on CYP3A metabolism (e.g.fluvastatin) can be considered. Patients should be monitored for signs and symptoms of myopathy.</p><p><strong>Effects of other medicinal products on clarithromycin</strong></p><p>Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carabamazepin, phenobarbital, St. Johns wort) may induce the metabolism of clarithromycin. This may result in sub-therapeutic levels of clarithromycin leading to a reduced efficacy. Furthermore it might be necessary to monitor the plasma levels of the CYP3A inducer, which could be increased owing to the inhibition of CYP3A by clarithromycin (see also the relevant product information for the CYP3A4 inhibitor administered). Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis.</p><p>The following drugs are known or suspected to affect circulating concentrations of clarithromycin; clarithromycin dosage adjustment or consideration of alternative treatments may be required.</p><p><u>Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine</u></p><p>Strong inducers of the cytochrome P450 metabolism system such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine may accelerate the metabolism of clarithromycin and thus lower the plasma levels of clarithromycin, while increasing those of 14-OH-clarithromycin, a metabolite that is also microbiologically active. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers.</p><p><u>Etravirine</u></p><p>Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has reduced activity against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.</p><p><u>Fluconazole</u></p><p>Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state minimum clarithromycin concentration (Cmin) and area under the curve (AUC) of 33% and 18% respectively. Steady state concentrations of the active metabolite 14-OH-clarithromycin were not significantly affected by concomitant administration of fluconazole. No clarithromycin dose adjustment is necessary.</p><p><u>Ritonavir</u></p><p>A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours resulted in a marked inhibition of the metabolism of clarithromycin. The clarithromycin Cmax increased by 31%, Cmin increased 182% and AUC increased by 77% with concomitant administration of ritonavir. An essentially complete inhibition of the formation of 14-OH-clarithromycin was noted. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function. However, for patients with renal impairment, the following dosage adjustments should be considered: For patients with CLCR 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients with CLCR &lt;30 mL/min the dose of clarithromycin should be decreased by 75%. Doses of clarithromycin greater than 1 g/day should not be coadministered with ritonavir.</p><p>Similar dose adjustments should be considered in patients with reduced renal function when ritonavir is used as a pharmacokinetic enhancer with other HIV protease inhibitors including atazanavir and saquinavir (see section below, Bi-directional drug interactions).</p><p><strong>Effect of clarithromycin on other medicinal products</strong></p><p><u>CYP3A-based interactions</u></p><p>Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug. Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g. carbamazepine) and/or the substrate is extensively metabolized by this enzyme.</p><p>Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.</p><p>The following drugs or drug classes are known or suspected to be metabolized by the same CYP3A isozyme: alprazolam, astemizole, carbamazepine, cilostazol, cisapride, cyclosporine, disopyramide, ergot alkaloids, lovastatin, methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g. warfarin), atypical antipsychotics (e.g. quetiapine), pimozide, quinidine, rifabutin, sildenafil, simvastatin, sirolimus, tacrolimus, terfenadine, triazolam and vinblastine but this list is not comprehensive. Drugs interacting by similar mechanisms through other isozymes within the cytochrome P450 system include phenytoin, theophylline and valproate.</p><p><u>Antiarrhythmics</u></p><p>There have been postmarketing reports of torsades de pointes occurring with concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QT prolongation during co-administration of clarithromycin with these drugs. Serum levels of quinidine and disopyramide should be monitored during clarithromycin therapy.</p><p>There have been post marketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide.</p><p><u>Oral hypoglycemic agents/Insulin</u></p><p>With certain hypoglycemic drugs such as nateglinide, and repaglinide, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypolgycemia when used concomitantly. Careful monitoring of glucose is recommended.</p><p><u>Omeprazole</u></p><p>Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole (40 mg daily) to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and t1/2 increased by 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when omeprazole was co-administered with clarithromycin.</p><p><u>Sildenafil, tadalafil, and vardenafil</u></p><p>Each of these phosphodiesterase inhibitors is metabolized, at least in part, by CYP3A, and CYP3A may be inhibited by concomitantly administered clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil or vardenafil would likely result in increased phosphodiesterase inhibitor exposure. Reduction of sildenafil, tadalafil and vardenafil dosages should be considered when these drugs are co-administered with clarithromycin.</p><p><u>Theophylline, carbamazepine</u></p><p>Results of clinical studies indicate there was a modest but statistically significant (p&le;0.05) increase of circulating theophylline or carbamazepine levels when either of these drugs were administered concomitantly with clarithromycin. Dose reduction may need to be considered.</p><p><u>Tolterodine</u></p><p>The primary route of metabolism for tolterodine is via the 2D6 isoform of cytochrome P450 (CYP2D6). However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. A reduction in tolterodine dosage may be necessary in the presence of CYP3A inhibitors, such as clarithromycin in the CYP2D6 poor metabolizer population.</p><p><u>Triazolobenzodiazepines (e.g. alprazolam, midazolam, triazolam)</u></p><p>When midazolam was co-administered with clarithromycin tablets (500 mg twice daily), midazolam AUC was increased 2.7-fold after intravenous administration of midazolam and 7-fold after oral administration. Concomitant administration of oral midazolam and clarithromycin should be avoided. If intravenous midazolam is co-administered with clarithromycin, the patient must be closely monitored to allow dose adjustment. The same precautions should also apply to other benzodiazepines that are metabolized by CYP3A, including triazolam and alprazolam.</p><p>For benzodiazepines which are not dependent on CYP3A for their elimination (temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.</p><p><strong>Other drug interactions</strong></p><p><u>Aminoglycosides</u></p><p>Caution is advised regarding concomitant administration of clarithromycin with other ototoxic drugs, especially with aminoglycosides. See 4.4</p><p><u>Colchicine</u></p><p>Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When clarithromycin and colchicine are administered together, inhibition of Pgp and/or CYP3A by clarithromycin may lead to increased exposure to colchicine(see section 4.3 and 4.4).</p><p><u>Digoxin</u></p><p>Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp). Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are administered together, inhibition of Pgp by clarithromycin may lead to increased exposure to digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have also been reported in post marketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Serum digoxin concentrations should be carefully monitored while patients are receiving digoxin and clarithromycin simultaneously.</p><p><u>Zidovudine</u></p><p>Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Because clarithromycin appears to interfere with the absorption of simultaneously administered oral zidovudine, this interaction can be largely avoided by staggering the doses of clarithromycin and zidovudine to allow for a 4-hour interval between each medication. This interaction does not appear to occur in paediatric HIV-infected patients taking clarithromycin suspension with zidovudine or dideoxyinosine. This interaction is unlikely when clarithromycin is administered via intravenous infusion.</p><p><u>Phenytoin and Valproate</u></p><p>There have been spontaneous or published reports of interactions of CYP3A inhibitors, including clarithromycin with drugs not thought to be metabolized by CYP3A (e.g. phenytoin and valproate). Serum level determinations are recommended for these drugs when administered concomitantly with clarithromycin. Increased serum levels have been reported</p><p><strong>Bi-directional drug interactions</strong></p><p><u>Atazanavir</u></p><p>Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Co-administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily) resulted in a 2- fold increase in exposure to clarithromycin and a 70% decrease in exposure to 14-OH-clarithromycin, with a 28% increase in the AUC of atazanavir. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function. For patients with moderate renal function (creatinine clearance 30 to 60 mL/min), the dose of clarithromycin should be decreased by 50%. For patients with creatinine clearance &lt;30 mL/min, the dose of clarithromycin should be decreased by 75% using an appropriate clarithromycin formulation.</p><p>Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</p><p><u>Calcium Channel Blockers</u></p><p>Caution is advised regarding the concomitant administration of clarithromycin and calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) due to the risk of hypotension. Plasma concentrations of clarithromycin as well as calcium channel blockers may increase due to the interaction. Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients taking clarithromycin and verapamil concomitantly.</p><p><u>Itraconazole</u></p><p>Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, leading to a bidirectional drug interaction. Clarithromycin may increase the plasma levels of itraconazole, while itraconazole may increase the plasma levels of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged pharmacologic effect.</p><p><u>Saquinavir</u></p><p>Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Concomitant administration of clarithromycin (500 mg twice daily) and saquinavir (soft gelatin capsules, 1200 mg three times daily) to 12 healthy volunteers resulted in steady-state AUC and Cmax values of saquinavir which were 177% and 187% higher than those seen with saquinavir alone. Clarithromycin AUC and Cmax values were approximately 40% higher than those seen with clarithromycin alone. No dose adjustment is required when the two drugs are co-administered for a limited time at the doses/formulations studied. Observations from drug interaction studies using the soft gelatin capsule formulation may not be representative of the effects seen using the saquinavir hard gelatin capsule. Observations from drug interaction studies performed with saquinavir alone may not be representative of the effects seen with saquinavir/ritonavir therapy. When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>The safety of clarithromycin for use during pregnancy has not been established. Based on variable results obtained from studies in mice, rats, rabbits and monkeys, the possibility of adverse effects on embryofoetal development cannot be excluded. Therefore, use during pregnancy is not advised without carefully weighing the benefits against risk.</p><p><strong><u>Breast-feeding</u></strong></p><p>The safety of clarithromycin for use during breast feeding of infants has not been established. Clarithromycin is excreted into human breast milk.</p><p><strong><u>Fertility</u></strong></p><p>There is no data available on the effect of clarithromycin on fertility in humans. In rats, the limited data available do not indicate any effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use machines. The potential for dizziness, vertigo, confusion and disorientation, which may occur with the medication, should be taken into account before patients drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of the safety profile</strong></p><p>The most frequent and common adverse reactions related to clarithromycin therapy for both adult and pediatric populations are abdominal pain, diarrhea, nausea, vomiting and taste perversion. These adverse reactions are usually mild in intensity and are consistent with the known safety profile of macrolide antibiotics (see section b of section 4.8).</p><p>There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without preexisting mycobacterial infections.</p><p><strong>b. Tabulated summary of adverse reactions</strong></p><p>The following table displays adverse reactions reported in clinical trials and from post-marketing experience with clarithromycin immediate-release tablets, granules for oral suspension, powder for solution for injection, extended release tablets and modified-release tablets.</p><p>The reactions considered at least possibly related to clarithromycin are displayed by system organ class and frequency using the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common (&ge;1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common &ge; 1/100 to &lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon &ge;1/1,000 to &lt; 1/100</strong></p></td><td style="vertical-align:top"><p><strong>Not Known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cellulitis<sup>1</sup>, candidiasis, gastroenteritis<sup>2</sup>, infection<sup>3</sup>, vaginal infection</p></td><td style="vertical-align:top"><p>Pseudomembranous colitis, erysipelas</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Leukopenia, neutropenia<sup>4</sup>, thrombocythemia<sup>3</sup>, eosinophilia<sup>4</sup></p></td><td style="vertical-align:top"><p>Agranulocytosis, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong><strong><sup>5</sup></strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactoid reaction<sup>1</sup>, Hypersensitivity</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, angioedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anorexia, decreased appetite</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety, nervousness<sup>3</sup>,</p></td><td style="vertical-align:top"><p>Psychotic disorder, confusional state, depersonalisation, depression, disorientation, hallucination, abnormal dreams, mania</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dysgeusia, headache, taste perversion</p></td><td style="vertical-align:top"><p>Loss of consciousness<sup>1</sup>, dyskinesia<sup>1</sup>, dizziness, somnolence<sup>6</sup>, tremor</p></td><td style="vertical-align:top"><p>Convulsion, ageusia, parosmia, anosmia, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo, hearing, impaired, tinnitus</p></td><td style="vertical-align:top"><p>Deafness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cardiac arrest<sup>1</sup>, atrial fibrillation<sup>1</sup>, electrocardiogram QT prolonged<sup>7</sup>, extrasystoles<sup>1</sup>, palpitations</p></td><td style="vertical-align:top"><p>Torsade de pointes<sup>7</sup>, ventricular tachycardia<sup>7</sup></p><p>ventricular fibrillation</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vasodilation<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hemorrhage<sup>8</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorder</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthma<sup>1</sup>, epistaxis<sup>2</sup>, pulmonary embolism<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhea<sup>9</sup>, vomiting, dyspepsia, nausea, abdominal pain</p></td><td style="vertical-align:top"><p>Esophagitis<sup>1</sup>, gastrooesophageal reflux disease<sup>2</sup>, gastritis, proctalgia<sup>2</sup>, stomatitis, glossitis, abdominal distension<sup>4</sup>, constipation, dry mouth, eructation, flatulence</p></td><td style="vertical-align:top"><p>Pancreatitis acute, tongue discolouration, tooth discoloration</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>Cholestasis<sup>4</sup>, hepatitis<sup>4</sup>, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased4</p></td><td style="vertical-align:top"><p>Hepatic failure<sup>10</sup>, jaundice hepatocellular</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash, hyperhidrosis</p></td><td style="vertical-align:top"><p>Dermatitis bullous<sup>1</sup>, pruritus, urticaria, rash maculo-papular<sup>3</sup></p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome<sup>5</sup>, toxic epidermal necrolysis<sup>5</sup>, drug rash with eosinophilia and systemic symptoms (DRESS), acne, acute generalised exanthematous pustulosis (AGEP)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscle spasms<sup>3</sup>, musculoskeletal stiffness<sup>1</sup>, myalgia<sup>2</sup></p></td><td style="vertical-align:top"><p>Rhabdomyolysis<sup>2, 11</sup>, myopathy</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased<sup>1</sup>, blood urea increased<sup>1</sup></p></td><td style="vertical-align:top"><p>Renal failure, nephritis interstitial</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Injection site phlebitis<sup>1</sup></p></td><td style="vertical-align:top"><p>Injection site pain<sup>1</sup>, injection site inflammation<sup>1</sup></p></td><td style="vertical-align:top"><p>Malaise<sup>4</sup>, pyrexia<sup>3</sup>, asthenia, chest pain<sup>4</sup>, chills<sup>4</sup>, fatigue<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Albumin globulin ratio abnormal<sup>1</sup>&nbsp;, blood alkaline phosphatase increased<sup>4</sup>, blood lactate dehydrogenase increased<sup>4</sup></p></td><td style="vertical-align:top"><p>International normalised ratio increased<sup>8</sup>, prothrombin time prolonged<sup>8</sup>, urine color abnormal</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;ADRs reported only for the Powder for Solution for Injection formulation</p><p><sup>2</sup>ADRs reported only for the Extended-Release Tablets formulation</p><p><sup>3</sup>&nbsp;ADRs reported only for the Granules for Oral Suspension formulation</p><p><sup>4</sup>&nbsp;ADRs reported only for the Immediate-Release Tablets formulation</p><p><sup>5</sup>,&nbsp;<sup>7, 9, 10,&nbsp;</sup>See section a)</p><p><sup>6, 8, 11</sup>&nbsp;See section c)</p><p><strong>c. Description of selected adverse reactions</strong></p><p>Injection site phlebitis, injection site pain, vessel puncture site pain, and injection site inflammation are specific to the clarithromycin intravenous formulation.</p><p>In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol (see section 4.3 and 4.4).</p><p>There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in elderly and/or patients with renal insufficiency, some with a fatal outcome (see sections 4.4 and 4.5).</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested (see section 4.5).</p><p>There have been rare reports of clarithromycin ER tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. In several reports, tablet residues have occurred in the context of diarrhea. It is recommended that patients who experience tablet residue in the stool and no improvement in their condition should be switched to a different clarithromycin formulation (e.g. suspension) or another antibiotic.</p><p>Special population: Adverse Reactions in Immunocompromised Patients (see section e)</p><p><strong>d. Paediatric populations</strong></p><p>Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension. There are insufficient data to recommend a dosage regimen for use of the clarithromycin IV formulation in patients less than 18 years of age.</p><p>Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.</p><p><strong>e. Other special populations</strong></p><p><em>Immunocompromised patients</em></p><p>In AIDS and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying signs of Human Immunodeficiency Virus (HIV) disease or intercurrent illness.</p><p>In adult patients, the most frequently reported adverse reactions by patients treated with total daily doses of 1,000 mg and 2,000 mg of clarithromycin were: nausea, vomiting, taste perversion, abdominal pain, diarrhea, rash, flatulence, headache, constipation, hearing disturbance, Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvate Transaminase (SGPT) elevations. Additional low-frequency events included dyspnoea, insomnia and dry mouth. The incidences were comparable for patients treated with 1,000 mg and 2,000 mg, but were generally about 3 to 4 times as frequent for those patients who received total daily doses of 4,000 mg of clarithromycin.</p><p>In these immunocompromised patients, evaluations of laboratory values were made by analysing those values outside the seriously abnormal level (i.e. the extreme high or low limit) for the specified test. On the basis of these criteria, about 2% to 3% of those patients who received 1,000 mg or 2,000 mg of clarithromycin daily had seriously abnormal elevated levels of SGOT and SGPT, and abnormally low white blood cell and platelet counts. A lower percentage of patients in these two dosage groups also had elevated Blood Urea Nitrogen levels. Slightly higher incidences of abnormal values were noted for patients who received 4,000 mg daily for all parameters except White Blood Cell.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>Healthcare professionals are asked to report any suspected adverse reactions at:</p><p>&nbsp;</p><p>&bull; Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC) ,Fax: +966-11-205-7662,</p><p>Call NPC at +966-11-2038222, Exts 2317-2356-2340.</p><p>Reporting Hotline: 19999,</p><p>E-mail: npc.drug@sfda.gov.sa &nbsp;,</p><p>Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&bull; Other GCC States: Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms of intoxication:</u></p><p>Reports indicate that the ingestion of large amounts of clarithromycin can be expected to produce gastrointestinal symptoms. One patient who had a history of bipolar disorder ingested eight grams of clarithromycin and showed altered mental status, paranoid behaviour, hypokalaemia and hypoxemia.</p><p><u>Therapy of intoxication:</u></p><p>Adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum levels are not expected to be appreciably affected by hemodialysis or peritoneal dialysis.</p><p>In the case of overdosage, clarithromycin IV (powder for solution for injection) should be discontinued and all other appropriate supportive measures should be instituted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Macrolides</p><p>ATC code: J01FA09</p><p><u>Mode of action:</u></p><p>Clarithromycin is a semi-synthetic derivative of erythromycin A. It exerts its antibacterial action by binding to the 50s ribosomal sub-unit of susceptible bacteria and suppresses protein synthesis. It is highly potent against a wide variety of aerobic and anaerobic gram-positive and gram-negative organisms. The minimum inhibitory concentrations (MICs) of clarithromycin are generally two-fold lower than the MICs of erythromycin.</p><p>The 14-hydroxy metabolite of clarithromycin also has antimicrobial activity. The MICs of this metabolite are equal or twofold higher than the MICs of the parent compound, except for H. influenzae where the 14-hydroxy metabolite is two-fold more active than the parent compound.</p><p><u>PK/PD relationship</u></p><p>Clarithromycin is extensively distributed into body tissues and fluids. Due to the high tissue penetration, intracellular concentrations higher than serum concentrations. The main pharmacodynamic parameters to predict macrolidenactiviteit are unconvincing established. The time above the MIC (T / MIC) is the best determinant for the efficacy of clarithromycin. Because the concentrations of clarithromycin in the lung tissues and epithelial tissue fluid reaches the plasma concentrations exceed, the use of plasma concentrations based parameters are insufficient to accurately predict response for respiratory infections.</p><p><u>Mechanisms of resistance:</u></p><p>Resistance mechanisms against macrolide antibiotics include alteration of the target site of the antibiotic or are based on modification and/or the active efflux of the antibiotic. Resistance development can be mediated via chromosomes or plasmids, be induced or exist constitutively. Macrolideresistant bacteria generate enzymes which lead to methylation of residual adenine at ribosomal RNA and consequently to inhibition of the antibiotic binding to the ribosome. Macrolide-resistant organisms are generally cross-resistant to lincosamides and streptogramine B based on methylation of the ribosomal binding site. Clarithromycin ranks among the strong inducers of this enzyme as well. Furthermore, macrolides have a bacteriostatic action by inhibiting the peptidyl transferase of ribosomes. A complete cross-resistance exists among clarithromycin, erythromycin and azithromycin. Methicillin-resistant staphylococci and penicillin-resistant Streptococcus pneumoniae are resistant to macrolides such as clarithromycin.</p><p><u>Breakpoints:</u></p><p>The following breakpoints for clarithromycin, separating susceptible organisms from resistant organisms, have been established by the European Committee for Antimicrobial Susceptibility Testing (EUCAST) 2010-04-27 (v 1.1)</p><p>&nbsp;</p><p><sup>A&nbsp;</sup>Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species not mentioned in the table or footnotes However, pharmacodynamic data for calculation of macrolide, lincosamines and streptogramins non-species related breakpoints are not robust, hence IE.</p><p><sup>B&nbsp;</sup>Erythromycin can be used to determine the susceptibility of the listed bacteria to the other macrolides (azithromycin, clarithromycin and roxithromycin</p><p><sup>C</sup>&nbsp;Clarithromycin is used for the eradication of H. pylori (MIC &le;0.25 mg/L for wild type isolates).</p><p><sup>D</sup>&nbsp;The correlation between H. influenzae macrolide MICs and clinical outcome is weak. Therefore, breakpoints for macrolides and related antibiotics were set to categorise wild type H. influenzae as intermediate.</p><p>Clarithromycin is used for the eradication of H. pylori; minimum inhibitory concentration (MIC) &le; 0.25 &mu;g/ml which has been established as the susceptible breakpoint by the Clinical and Laboratory Standards Institute (CLSI).</p><p><em>Susceptibility:</em></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalance of resistance is such that the utility of the agent in atleast some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic, Gram-positive microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;</em>group F</p></td></tr><tr><td style="vertical-align:top"><p><em>Corynebacterium diptheriae</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic, Gram-negative microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Bordetella pertusis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Pasteurella multocida</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Legionella&nbsp;</em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anaerobic microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Clostridium&nbsp;</em>spp., other than<em>&nbsp;C. difficile</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Other microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Mycoplasma pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Chlamydia trachomatis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Clamydophila pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Clamydophilapsitacci</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Mycobacterium spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem#</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic, Gram-positive microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;</em>group A*, C, G</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;</em>group B</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus viridans</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus spp</em><em><sup>+</sup></em></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus,&nbsp;</em>methicillin-susceptible and methicillin-resistant+</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae*+</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus epidermidis+</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic, Gram-negative microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae$</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Helicobacter pylori</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Anaerobic microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacteroides&nbsp;</em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><em>Peptococcus/Peptostreptococcus&nbsp;</em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic, Gram-negative microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriacea</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Anaerobic microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Fusobacterium&nbsp;</em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Other microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Mycobacterium tuberculosis</em></p></td></tr></tbody></table><p># &ge; 10% resistance in at least one country of the European Union</p><p>* Species against efficacy has been demonstrated in clinical investigations (if susceptible)</p><p>+ Indicates species for which a high rate of resistance (i.e. greater than 50%) have been observed in one or more area/country/region(s) of the EU</p><p>&sect; Breakpoints for macrolides and related antibiotics were set to categorise wild type&nbsp;<em>H. influenzae</em>&nbsp;as intermediate</p><p><strong>Other information:</strong></p><p>Susceptibility and resistance of Streptococcus pneumoniae and Streptococcus spp. to clarithromycin can be predicted by testing erythromycin.</p><p>Most available clinical experience from controlled randomised clinical trials indicate that clarithromycin 500 mg twice daily in combination with another antibiotic e.g. amoxicillin or metronidazole and e.g. omeprazole (given at approved levels) for 7 days achieve &gt; 80% H. pylori eradication rate in patients with gastro-duodenal ulcers. As expected, significantly lower eradication rates were observed in patients with baseline metronidazole-resistant H. pylori isolates. Hence, local information on the prevalence of resistance and local therapeutic guidelines should be taken into account in the choice of an appropriate combination regimen for H. pylori eradication therapy. Furthermore, in patients with persistent infection, potential development of secondary resistance (in patients with primary susceptible strains) to an antimicrobial agent should be taken into the considerations for a new retreatment regimen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption:</u></p><p>Clarithromycin is rapidly and well absorbed from the gastrointestinal tract &ndash; primarily in the jejunum &ndash; but undergoes extensive first-pass metabolism after oral administration. The absolute bioavailability of a 250-mg clarithromycin tablet is approximately 50%. Food slightly delays the absorption but does not affect the extent of bioavailability. Therefore, clarithromycin tablets may be given without regard to food. Due to its chemical structure (6-O-Methylerythromycin) clarithromycin is quite resistant to degradation by stomach acid. Peak plasma levels of 1 &ndash; 2 &mu;g/ml clarithromycin were observed in adults after oral administration of 250 mg twice daily. After administration of 500 mg clarithromycin twice daily the peak plasma level was 2.8 &mu;g/ml. After administration of 250 mg clarithromycin twice daily the microbiologically active 14-hydroxy metabolite attains peak plasma concentrations of 0.6 &mu;g/ml. Steady state is attained within 2 days of dosing.</p><p><u>Distribution:</u></p><p>Clarithromycin penetrates well into different compartments with an estimated volume of distribution of 200-400 l. Clarithromycin provides concentrations in some tissues that are several times higher than the circulating drug levels. Increased levels have been found in both tonsils and lung tissue. Clarithromycin also penetrates the gastric mucus.</p><p>Clarithromycin is approximately 70% bound to plasma proteins at therapeutic levels.</p><p><u>Biotransformation and elimination:</u></p><p>Clarithromycin is rapidly and extensively metabolised in the liver. Metabolism is in the liver involving the P450 cytochrome system. Three metabolites are described: N-demethyl clarithromycin, decladinosyl clarithromycin and 14-hydroxy clarithromycin. The pharmacokinetics of clarithromycin is non-linear due to saturation of hepatic metabolism at high doses. Elimination half-life increased from 2-4 hours following administration of 250 mg clarithromycin twice daily to 5 hours following administration of 500 mg clarithromycin twice daily. The half-life of the active 14-hydroxy metabolite ranges between 5 to 6 hours following administration of 250 mg clarithromycin twice daily.</p><p>Approximately 20 -40% of clarithromycin is excreted as the unchanged active substance in the urine. This proportion is increased when the dose is increased. An additional 10% to 15% is excreted in the urine as 14-hydroxy metabolite. The rest is excreted in the faeces.Renal insufficiency increases clarithromycin levels in plasma, if the dose is not decreased. Total plasma clearance has been estimated to approximately 700 mL/min (11,7 mL/s), with a renal clearance of approximately 170 mL/min (2,8 mL/s).</p><p><strong>Special populations:</strong></p><p>Renal impairment: Reduced renal insufficiency function results in increased plasma levels of clarithromycin and the active metabolite levels in plasma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 4-week-studies in animals, toxicity of clarithromycin was found to be related to the dose and to the duration of the treatment. In all species, the first signs of toxicity were observed in the liver, in which lesions were seen within 14 days in dogs and monkeys. The systemic levels of exposure, related to this toxicity, are not known in detail, but toxic doses were clearly higher than the therapeutic doses recommended for humans. Other tissues affected included the stomach, thymus and other lymphoid tissues as well as the kidneys. At near therapeutic doses conjunctival injection and lacrimation occurred only in dogs. At a dose of 400 mg/kg/day some dogs and monkeys developed corneal opacities and/or oedema.</p><p>No mutagenic effects were found in&nbsp;<em>in vitro</em>- and&nbsp;<em>in vivo</em>&nbsp;-studies with clarithromycin</p><p>Studies on reproduction toxicity showed that administration of clarithromycin at doses 2x the clinical dose in rabbit (i.v.) and x10 the clinical dose in monkey (p.o.) resulted in an increased incidence of spontaneous abortions. These doses were related to maternal toxicity. No embryotoxicity or teratogenicity was noted in rat studies. Cardiovascular malformations were observed in rats treated with doses of 150 mg/kg/d. In mouse at doses x70 the clinical dose cleft palate occurred at varying incidence (3-30%).</p><p>Clarithromycin has been found in the milk of lactating animals.</p><p>In 3-day old mice and rats, the LD50 values were approximately half those in adult animals. Juvenile animals presented similar toxicity profiles to mature animals although enhanced nephrotoxicity in neonatal rats has been reported in some studies. Slight reductions in erythrocytes, platelets and leukocytes have also been found in juvenile animals.</p><p>Clarithromycin has not been tested for carcinogenicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Core</strong>: Polysorbate, Colloidal anhydrous silica, Microcrystalline Cellulose, Maize Starch, Povidone, Pregelatinised Starch, Magnesium Stearate, Stearic Acid, Purified Talc, Croscarmellose sodium.</p><p><strong>Coating</strong>: Purified Talc, Hypromellose, PEG, Titanium dioxide, Simethicone emulsion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm; C. Store in a dry place. Protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>14 Tablets are packed in Aluminium-Aluminium blisters as 7&rsquo;s blister X 2 and placed in a product specific carton along with a patient information leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Globalpharma Co. L.L.C., Dubai Investment Park, Jebel Ali, Dubai, U.A.E.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07th  May 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>